These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 21436438)

  • 1. Can treatment costs be tamed?
    Malakoff D
    Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
    [No Abstract]   [Full Text] [Related]  

  • 2. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soaring price of cancer drugs leads plans to new approaches.
    Sipkoff M
    Manag Care; 2007 Aug; 16(8):12-3. PubMed ID: 17886533
    [No Abstract]   [Full Text] [Related]  

  • 4. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 5. [The cost of chemotherapy].
    Lévy C; Bonastre J
    Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient cancer drug costs: changes, drivers, and the future.
    Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
    Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limits on Medicare's ability to control rising spending on cancer drugs.
    Bach PB
    N Engl J Med; 2009 Feb; 360(6):626-33. PubMed ID: 19176475
    [No Abstract]   [Full Text] [Related]  

  • 8. Realigning incentives for developing and pricing new anticancer treatments.
    Howard DH
    JAMA; 2011 Jun; 305(22):2347-8. PubMed ID: 21642689
    [No Abstract]   [Full Text] [Related]  

  • 9. [Innovative therapy, early and cost-benefit assessment].
    Dierks C
    Onkologie; 2012; 35 Suppl 2():7. PubMed ID: 22517064
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral/infusion cancer drug parity begins to raise health plan costs.
    Carroll J
    Manag Care; 2012 Jan; 21(1):7-8. PubMed ID: 22334937
    [No Abstract]   [Full Text] [Related]  

  • 11. How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States.
    Ramsey SD
    J Clin Oncol; 2007 Jan; 25(2):175-9. PubMed ID: 17210936
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer treatment cost in the United States: has the burden shifted over time?
    Tangka FK; Trogdon JG; Richardson LC; Howard D; Sabatino SA; Finkelstein EA
    Cancer; 2010 Jul; 116(14):3477-84. PubMed ID: 20564103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
    Navarro RP; Morrow T; Baran R
    Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical and value issues in insurance coverage for cancer treatment.
    Brock DW
    Oncologist; 2010; 15 Suppl 1():36-42. PubMed ID: 20237216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "It's the economy, stupid": strategies for improved cost containment in cancer treatment.
    Sleijfer S
    Clin Pharmacol Ther; 2014 Apr; 95(4):365-7. PubMed ID: 24646487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Era of personalized medicine may herald end of soaring cancer costs.
    Keogh B
    J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
    [No Abstract]   [Full Text] [Related]  

  • 17. [Economic effects of "molecular" medicine].
    Riemann JF
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1740. PubMed ID: 17713881
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicare cost containment strategy targets several oncology drugs.
    Twombly R
    J Natl Cancer Inst; 2004 Sep; 96(17):1268-70. PubMed ID: 15339960
    [No Abstract]   [Full Text] [Related]  

  • 19. Expensive cancer therapies: unintended effects.
    Delude CM
    J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
    [No Abstract]   [Full Text] [Related]  

  • 20. Use and coverage of novel cancer agents in managed care.
    Bailes JS
    Semin Oncol; 1994 Dec; 21(6 Suppl 14):34-7. PubMed ID: 7992098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.